Mechanism of action of statins and fibrates;Mécanismes d'action des statines et des fibrates

Therapie

Volumn 58, Issue 1, 2003, Pages 5-14

  Duriez, Patrick ^a  

^a INSTITUT PASTEUR DE LILLE   (France)

Author keywords

Dyslipoproteinaemias; Fibrates; PPAR ; Statins

Indexed keywords

FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; STATIN; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

CATABOLISM; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; COMPLEX FORMATION; DRUG EFFICACY; DRUG MECHANISM; DYSLIPIDEMIA; ENDOPLASMIC RETICULUM; ENZYME INHIBITION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; LIPOPROTEIN METABOLISM; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0038284773     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: 10.2515/therapie:2003002     Document Type: Review

References (59)

1. Sposito AC, Chapman MJ. Statin therapy in acute coronary syndromes: mechanistic insight into clinical benefit. Arterioscler Thromb Vasc Biol 2002; 22: 1524-34
2. Chao Y, Chen JS, Hunt VM, et al. Lowering of plasma cholesterol levels in animals by lovastatin and simvastatin. Eur J Clin Pharmacol 1991; 40 Suppl. 1: S11-4
3. Forster LF, Stewart G, Bedford D, et al. Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates. Atherosclerosis 2002; 164: 129-45
4. Brown MS, Goldstein JL. A receptor- mediated pathway for cholesterol homeostasis. Science 1986; 232: 34-47
5. Vega GL, Grundy SM. Influence of lovastatin therapy on metabolism of low density lipoproteins in mixed hyperlipidaemia. J Intern Med 1991; 230: 341-50
6. Bilheimer DW, Grundy SM, Brown MS, et al. Mevinolin stimulates receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. Trans Assoc Am Phys 1983; 96: 1-9
7. Albers-Schonberg G, Joshua H, Lopez MB, et al. Dihydromevinolin, a potent hypocholesterolemic metabolite produced by aspergillus terreus. J Antibiot (Tokyo) 1981; 34: 507-12
8. Alberts AW. Discovery, biochemistry and biology of lovastatin. Am J Cardiol 1988; 62: 10J-5J
9. Endo A, Kuroda M, Tsujita Y. ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by penicillium citrinium. J Antibiot (Tokyo) 1976; 29: 1346-8
10. Brown MS, Goldstein JL. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 1997; 89: 331-40
11. Dooley KA, Millinder S, Osborne TF. Sterol regulation of 3-hydroxy-3-methylglutaryl-coenzyme A synthase gene through a direct interaction between sterol regulatory element binding protein and the trimeric CCAAT-binding factor/nuclear factor Y. J Biol Chem 1998; 273: 1349-56
12. Edwards PA, Lan SF, Fogelman AM. Alterations in the rates of synthesis and degradation of rat liver 3-hydroxy-3-methylglutaryl coenzyme A reductase produced by cholestyramine and mevinolin. J Biol Chem 1983; 258: 10219-22
13. Horton JD, Shimomura I, Brown MS, et al. Activation of cholesterol synthesis in preference to fatty acid synthesis in liver and adipose tissue of transgenic mice overproducing sterol regulatory element-binding protein-2. J Clin Invest 1998; 101: 2331-9
14. Kita T, Brown MS, Goldstein JL. Feedback regulation of 3-hydroxy-3methylglutaryl coenzyme A reductase in livers of mice treated with mevinolin, a competitive inhibitor of the reductase. J Clin Invest 1980; 66: 1094-100
15. Li AC, Tanaka RD, Callaway K, et al. Localization of 3-hydroxy-3-methylglutaryl CoA reductase and 3-hydroxy-3-methylglutaryl CoA synthase in the rat liver and intestine is affected by cholestyramine and mevinolin. J Lipid Res 1988; 29: 781-96
16. Singer II, Scott S, Kazazis DM, et al. Lovastatin, an inhibitor of cholesterol synthesis, induces hydroxymethylglutaryl-coenzyme A reductase directly on membranes of expanded smooth endoplasmic reticulum in rat hepatocytes. Proc Natl Acad Sci USA 1988; 85: 5264-8
17. Ma PT, Gil G, Sudhof TC, et al. Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits. Proc Natl Acad Sci USA. 1986; 83: 8370-4
18. Makar RS, Lipsky PE, Cuthbert JA. Sterol-independent, sterol response elementdependent, regulation of low density lipoprotein receptor gene expression. J Lipid Res 1998; 39: 1647-54
19. Pak YK. Serum response element-like sequences of the human low density lipoprotein receptor promoter: possible regulation sites for sterol-independent transcriptional activation. Biochem Mol Biol Int 1996; 38: 31-6
20. Brown MS, Goldstein JL. A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood. Proc Natl Acad Sci USA. 1999; 96: 11041-8
21. Nohturfft A, Brown MS, Goldstein JL. Topology of SREBP cleavage-activating protein, a polytopic membrane protein with a sterol-sensing domain. J Biol Chem 1998; 273: 17243-50
22. Sakai J, Nohturfft A, Goldstein JL, et al. Cleavage of sterol regulatory elementbinding proteins (SREBPs) at site-1 requires interaction with SREBP cleavageactivating protein: evidence from in vivo competition studies. J Biol Chem 1998; 273: 5785-93
23. Brown AJ, Sun L, Feramisco JD, et al. Cholesterol addition to ER membranes alters conformation of SCAP, the SREBP escort protein that regulates cholesterol metabolism. Mol Cell 2002; 10: 237-45
24. Yang T, Espenshade PJ, Wright ME, et al. Crucial step in cholesterol homeostasis: sterols promote binding of SCAP to INSIG-1, a membrane protein that facilitates retention of SREBPs in ER. Cell 2002; 110: 489-500
25. Yabe D, Brown MS, Goldstein JL. Insig-2, a second endoplasmic reticulum protein that binds SCAP and blocks export of sterol regulatory element-binding proteins. Proc Natl Acad Sci USA 2002; 99: 12753-8
26. Cheng D, Espenshade PJ, Slaughter CA, et al. Secreted site-1 protease cleaves peptides corresponding to luminal loop of sterol regulatory element-binding proteins. J Biol Chem 1999; 274: 22805-12
27. Sakai J, Rawson RB, Espenshade PJ, et al. Molecular identification of the sterolregulated luminal protease that cleaves SREBPs and controls lipid composition of animal cells. Mol Cell 1998; 2: 505-14
28. Nohturfft A, DeBose-Boyd RA, Scheek S, et al. Sterols regulate cycling of SREBP cleavage-activating protein (SCAP) between endoplasmic reticulum and Golgi. Proc Natl Acad Sci USA 1999; 96: 11235-40
29. Duncan EA, Brown MS, Goldstein JL, et al. Cleavage site for sterol-regulated protease localized to a leu-Ser bond in the lumenal loop of sterol regulatory element-binding protein-2. J Biol Chem 1997; 272: 12778-85
30. Espenshade PJ, Cheng D, Goldstein JL, et al. Autocatalytic processing of site-1 protease removes propeptide and permits cleavage of sterol regulatory elementbinding proteins. J Biol Chem 1999; 274: 22795-804
31. Sakai J, Duncan EA, Rawson RB, et al. Sterol-regulated release of SREBP-2 from cell membranes requires two sequential cleavages, one within a transmembrane segment. Cell 1996; 85: 1037-46
32. Schoonjans K, Staels B, Auwerx J. The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta 1996; 1302: 93-109
33. Desager JP, Horsmans Y, Vandenplas C, et al. Pharmacodynamic activity of lipoprotein lipase and hepatic lipase, and pharmacokinetic parameters measured in normolipidaemic subjects receiving ciprofibrate (100 or 200 mg/day) or micronised fenofibrate (200 mg/day) therapy for 23 days. Atherosclerosis 1996; 124: S65-73
34. Heller F, Harvengt C. Effects of clofibrate, bezafibrate fenofibrate and probucol on plasma lipolytic enzymes in normolipaemic subjects. Eur J Clin Pharmacol 1983; 25: 57-63
35. Haubenwallner S, Essenburg AD, Barnett BC, et al. Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein C-III expression: a potential physiologic basis for their mode of action. J Lipid Res 1995; 36: 2541-51
36. Bard JM, Parra HJ, Camare R, et al. A multicenter comparison of the effects of simvastatin and fenofibrate therapy in severe primary hypercholesterolemia, with particular emphasis on lipoproteins defined by their apolipoprotein composition. Metabolism 1992; 41: 498-503
37. Cattin L, Da Col PG, Feruglio FS, et al. Efficacy of ciprofibrate in primary type II and IV hyperlipidemia: the Italian multicenter study. Clin Ther 1990; 12: 482-8
38. Malmendier CL, Delcroix C. Effects of fenofibrate on high and low density lipoprotein metabolism in heterozygous familial hypercholesterolemia. Atherosclerosis 1985; 55: 161-9
39. Steinmetz A, Schwartz T, Hehnke U, et al. Multicenter comparison of micronized fenofibrate and simvastatin in patients with primary type IIA or IIB hyperlipoproteinemia. J Cardiovasc Pharmacol 1996; 27: 563-70
40. Berthou L, Duverger N, Emmanuel F, et al. Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-1 transgenic mice. J Clin Invest 1996; 97: 2408-16
41. Vu-Dac N, Schoonjans K, Kosykh V, et al. Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. J Clin Invest 1995; 96: 741-50
42. Vu-Dac N, Schoonjans K, Laine B, et al. Negative regulation of the human apolipoprotein A-I promoter by fibrates can be attenuated by the interaction of the peroxisome proliferator-activated receptor with its response element. J Biol Chem 1994; 269: 31012-8
43. Martin G, Schoonjans K, Lefebvre AM, et al. Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARalpha and PPARgamma activators. J Biol Chem 1997; 272: 28210-7
44. Brandt JM, Djouadi F, Kelly DP. Fatty acids activate transcription of the muscle carnitine palmitoyltransferase I gene in cardiac myocytes via the peroxisome proliferator-activated receptor alpha. J Biol Chem 1998; 273: 23786-92
45. Mascaro C, Acosta E, Ortiz JA, et al. Control of human muscle-type carnitine palmitoyltransferase I gene transcription by peroxisome proliferator-activated receptor. J Biol Chem 1998; 273: 8560-3
46. Schoonjans K, Peinado-Onsurbe J, Lefebvre AM, et al. PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J 1996; 15: 5336-48
47. Hertz R, Bishara-Shieban J, Bar-Tana J. Mode of action of peroxisome proliferators as hypolipidemic drugs: suppression of apolipoprotein C-III. J Biol Chem 1995; 270: 13470-5
48. Staels B, Vu-Dac N, Kosykh VA, et al. Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase: a potential mechanism for the hypolipidemic action of fibrates. J Clin Invest 1995; 95: 705-12
49. Berthou L, Saladin R, Yaqoob P, et al. Regulation of rat liver apolipoprotein A-1, apolipoprotein A-11 and acyl-coenzyme A oxidase gene expression by fibrates and dietary fatty acids. Eur J Biochem 1995; 232: 179-87
50. Chinetti G, Lestavel S, Becher V, et al. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCAI pathway. Nat Med 2001; 7: 53-8
51. Chinetti G, Gbaguidi FG, Griglio S, et al. CLA-1/SR-B1 is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. Circulation 2000; 101: 2411-7
52. Poynter ME, Daynes RA. Peroxisome proliferator-activated receptor alpha activation modulates cellular redox status, represses nuclear factor-kappaB signaling, and reduces inflammatory cytokine production in aging. J Biol Chem 1998; 273: 32833-41
53. Staels B, Koenig W, Habib A, et al. Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators. Nature 1998; 393: 790-3
54. Delerive P, De Bosscher K, Vanden Berghe W, et al. DNA binding-independent induction of IkappaBalpha gene transcription by PPARalpha. Mol Endocrinol 2002; 16: 1029-39
55. Delerive P, De Bosscher K, Besnard S, et al. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem 1999; 274: 32048-54
56. Delerive P, Martin-Nizard F, Chinetti G, et al. PPAR activators inhibit thrombininduced endothelin-I production in human vascular endothelial cells. Circulation 1998; 98. 17: 1-406-2137
57. Neve BP, Corseaux D, Chinetti G, et al. PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages. Circulation 2001; 103: 207-12
58. Gervois P, Vu-Dac N, Kleemann R, et al. Negative regulation of human fibrinogen gene expression by peroxisome proliferator-activated receptor alpha agonists via inhibition of CCAAT box/enhancer-binding protein beta. J Biol Chem 2001; 276: 33471-7
59. Martin G, Duez H, Blanquart C, et al. Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I. J Clin Invest 2001; 107: 1423-32